Recent advances in epilepsy

1.

Gastaut H, Caveness W, Landolt H et al (1964) A proposed international classification of epileptic seizures. Epilepsia 5:297–306. doi:10.1111/j.1528-1157.1964.tb03337.x CrossRef

2.

Merlis JK (1970) Proposal for an international classification of the epilepsies. Epilepsia 11:114–119. doi:10.1111/j.1528-1157.1970.tb03873.x PubMedCrossRef

3.

Commission on Classification and Terminology of the International League Against Epilepsy (1981) Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22:489–501. doi:10.1111/j.1528-1157.1981.tb06159.x CrossRef

4.

Engel J (2001) A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE task force on classification and terminology. Epilepsia 42:796–803. doi:10.1046/j.1528-1157.2001.10401.x PubMedCrossRef

5.

Berg AT, Berkovic SF, Brodie MJ et al (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 51:676–685. doi:10.1111/j.1528-1167.2010.02522.x PubMedCrossRef

6.

Scheffer IE, French J, Hirsch E et al (2016) Classification of the epilepsies: new concepts for discussion and debate-special report of the ILAE Classification Task Force of the Commission for Classification and Terminology. Epilepsia Open 1:37–44. doi:10.1002/epi4.5 CrossRef

7.

Fisher RS, Acevedo C, Arzimanoglou A et al (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55:475–482. doi:10.1111/epi.12550 PubMedCrossRef

8.

Krumholz A, Wiebe S, Gronseth GS et al (2015) Evidence-based guideline: management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 84:1705–1713. doi:10.1212/WNL.0000000000001487 PubMedPubMedCentralCrossRef

9.

Lugaresi E, Cirignotta F, Montagna P (1986) Nocturnal paroxysmal dystonia. J Neurol Neurosurg Psychiatry 49:375–380. doi:10.1136/JNNP.49.4.375 PubMedPubMedCentralCrossRef

10.

Tinuper P, Cerullo A, Cirignotta F et al (1990) Nocturnal paroxysmal dystonia with short-lasting attacks: three cases with evidence for an epileptic frontal lobe origin of seizures. Epilepsia 31:549–556. doi:10.1111/j.1528-1157.1990.tb06105.x PubMedCrossRef

11.

Parrino L, Halasz P, Tassinari CA, Terzano MG (2006) CAP, epilepsy and motor events during sleep: the unifying role of arousal. Sleep Med Rev 10:267–285. doi:10.1016/j.smrv.2005.12.004 PubMedCrossRef

12.

Trinka E, Cock H, Hesdorffer D et al (2015) A definition and classification of status epilepticus: report of the ILAE task force on classification of status epilepticus. Epilepsia 56:1515–1523. doi:10.1111/epi.13121 PubMedCrossRef

13.

Treiman DM, Walton NY, Kendrick C (1990) A progressive sequence of electroencephalographic changes during generalized convulsive status epilepticus. Epilepsy Res 5:49–60. doi:10.1016/0920-1211(90)90065-4 PubMedCrossRef

14.

Treiman DM, Meyers PD, Walton NY et al (1998) A comparison of four treatments for generalized convulsive status epilepticus. N Engl J Med 339:792–798. doi:10.1056/NEJM199809173391202 PubMedCrossRef

15.

Welch RD, Nicholas K, Durkalski-Mauldin VL et al (2015) Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population. Epilepsia 56:254–262. doi:10.1111/epi.12905 PubMedPubMedCentralCrossRef

16.

Silbergleit R, Durkalski V, Lowenstein D et al (2012) Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 366:591–600. doi:10.1056/NEJMoa1107494 PubMedPubMedCentralCrossRef

17.

Kapur J, Macdonald RL (1997) Rapid seizure-induced reduction of benzodiazepine and Zn ²⁺ sensitivity of hippocampal dentate granule cell GABA A receptors. J Neurosci 17:7532–7540PubMedPubMedCentral

18.

Kapur J, Stringer JL, Lothman EW (1989) Evidence that repetitive seizures in the hippocampus cause a lasting reduction of GABAergic inhibition. J Neurophysiol 61:417–426PubMed

19.

Goodkin HP, Joshi S, Mtchedlishvili Z et al (2008) Subunit-specific trafficking of GABA(A) receptors during status epilepticus. J Neurosci 28:2527–2538. doi:10.1523/JNEUROSCI.3426-07.2008 PubMedPubMedCentralCrossRef

20.

Naylor DE (2005) Trafficking of GABAA receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 25:7724–7733. doi:10.1523/JNEUROSCI.4944-04.2005 PubMedCrossRef

21.

Naylor DE, Liu H, Niquet J, Wasterlain CG (2013) Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus. Neurobiol Dis 54:225–238. doi:10.1016/j.nbd.2012.12.015 PubMedPubMedCentralCrossRef

22.

Löscher W (2015) Single versus combinatorial therapies in status epilepticus: novel data from preclinical models. Epilepsy Behav 49:20–25. doi:10.1016/j.yebeh.2015.02.027 PubMedCrossRef

23.

Trinka E (2011) What is the evidence to use new intravenous AEDs in status epilepticus? Epilepsia 52:35–38. doi:10.1111/j.1528-1167.2011.03232.x PubMedCrossRef

24.

Navarro V, Dagron C, Elie C et al (2016) Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial. Lancet Neurol 15:47–55. doi:10.1016/S1474-4422(15)00296-3 PubMedCrossRef

25.

Shorvon S, Ferlisi M (2011) The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 134:2802–2818. doi:10.1093/brain/awr215 PubMedCrossRef

26.

Shorvon S, Ferlisi M (2012) The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain 135:2314–2328. doi:10.1093/brain/aws091 PubMedCrossRef

27.

Yasiry Z, Shorvon SD (2014) The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure 23:167–174. doi:10.1016/j.seizure.2013.12.007 PubMedCrossRef

28.

Malamiri RA, Ghaempanah M, Khosroshahi N et al (2012) Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. Eur J Paediatr Neurol 16:536–541. doi:10.1016/j.ejpn.2012.01.012 PubMedCrossRef

29.

Su Y, Liu G, Tian F et al (2016) Phenobarbital versus valproate for generalized convulsive status epilepticus in adults: a prospective randomized controlled trial in China. CNS Drugs 30:1201–1207. doi:10.1007/s40263-016-0388-6 PubMedCrossRef

30.

Vardhan Gupta H, Kaur G, Chawla R et al (2015) comparative assessment for the efficacy of valproate and phenytoin for controlling seizures in patients of convulsive status epilepticus: a randomized controlled trial. J Adv Med Dent Sci Res 3:S15–S20

31.

Shekh-Ahmad T, Mawasi H, McDonough JH et al (2015) The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Epilepsy Behav 49:298–302. doi:10.1016/j.yebeh.2015.04.012 PubMedCrossRef

32.

Bleck T, Cock H, Chamberlain J et al (2013) The established status epilepticus trial 2013. Epilepsia 54:89–92. doi:10.1111/epi.12288 PubMedPubMedCentralCrossRef

33.

Legriel S, Pico F, Tran-Dinh Y-R et al (2016) Neuroprotective effect of therapeutic hypothermia versus standard care alone after convulsive status epilepticus: protocol of the multicentre randomised controlled trial HYBERNATUS. Ann Intensiv Care 6:54. doi:10.1186/s13613-016-0159-z CrossRef

34.

Johnson JW, Glasgow NG, Povysheva NV (2015) Recent insights into the mode of action of memantine and ketamine. Curr Opin Pharmacol 20:54–63. doi:10.1016/j.coph.2014.11.006 PubMedCrossRef

35.

Synowiec AS, Singh DS, Yenugadhati V et al (2013) Ketamine use in the treatment of refractory status epilepticus. Epilepsy Res 105:183–188. doi:10.1016/j.eplepsyres.2013.01.007 PubMedCrossRef

36.

Hoefler J, Rohracher A, Kalss G et al (2016) (S)-Ketamine in refractory and super-refractory status epilepticus: a retrospective study. CNS Drugs 30:869–876. doi:10.1007/s40263-016-0371-2 CrossRef

37.

Gaspard N, Foreman B, Judd LM et al (2013) Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia 54:1498–1503. doi:10.1111/epi.12247 PubMedPubMedCentralCrossRef

38.

Rosati A, Ilvento L, L’Erario M et al (2016) Efficacy of ketamine in refractory convulsive status epilepticus in children: a protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01). BMJ Open 6:e011565. doi:10.1136/bmjopen-2016-011565 PubMedPubMedCentralCrossRef

39.

Legriel S, Lemiale V, Schenck M et al (2016) Hypothermia for neuroprotection in convulsive status epilepticus. N Engl J Med 375:2457–2467. doi:10.1056/NEJMoa1608193 PubMedCrossRef

40.

Irani SR, Alexander S, Waters P et al (2010) Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 133:2734–2748. doi:10.1093/brain/awq213 PubMedPubMedCentralCrossRef

41.

Titulaer MJ, McCracken L, Gabilondo I et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12:157–165. doi:10.1016/S1474-4422(12)70310-1 PubMedPubMedCentralCrossRef

42.

Dogan Onugoren M, Deuretzbacher D, Haensch CA et al (2015) Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series. J Neurol Neurosurg Psychiatry 86:965–972. doi:10.1136/jnnp-2014-308814 PubMedCrossRef

43.

Irani SR, Michell AW, Lang B et al (2011) Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 69:892–900. doi:10.1002/ana.22307 PubMedCrossRef

44.

Wagner J, Schoene-Bake J-C, Malter MP et al (2013) Quantitative FLAIR analysis indicates predominant affection of the amygdala in antibody-associated limbic encephalitis. Epilepsia 54:1679–1687. doi:10.1111/epi.12320 PubMedCrossRef

45.

Irani SR, Stagg CJ, Schott JM et al (2013) Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 136:3151–3162. doi:10.1093/brain/awt212 PubMedCrossRef

46.

Bien CG, Urbach H, Schramm J et al (2007) Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy. Neurology 69:1236–1244. doi:10.1212/01.wnl.0000276946.08412.ef PubMedCrossRef

47.

Vanli-Yavuz EN, Erdag E, Tuzun E et al (2016) Neuronal autoantibodies in mesial temporal lobe epilepsy with hippocampal sclerosis. J Neurol Neurosurg Psychiatry 87:684–692. doi:10.1136/jnnp-2016-313146 PubMedCrossRef

48.

Brenner T, Sills GJ, Hart Y et al (2013) Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia 54:1028–1035. doi:10.1111/epi.12127 PubMedCrossRef

49.

Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342:314–319. doi:10.1056/NEJM200002033420503 PubMedCrossRef

50.

Brodie MJ (2016) Outcomes in newly diagnosed epilepsy in adolescents and adults: insights across a generation in Scotland. Seizure. doi:10.1016/j.seizure.2016.08.010 PubMed

51.

Callaghan B, Schlesinger M, Rodemer W et al (2011) Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia 52:619–626. doi:10.1111/j.1528-1167.2010.02929.x PubMedPubMedCentralCrossRef

52.

Luciano AL, Shorvon SD (2007) Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 62:375–381. doi:10.1002/ana.21064 PubMedCrossRef

53.

Choi H, Heiman G, Pandis D et al (2008) Seizure remission and relapse in adults with intractable epilepsy: a cohort study. Epilepsia 49:1440–1445. doi:10.1111/j.1528-1167.2008.01601.x PubMedPubMedCentralCrossRef

54.

Coulter DA, Huguenard JR, Prince DA (1989) Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol 25:582–593. doi:10.1002/ana.410250610 PubMedCrossRef

55.

Jasper H, Kershman J, Gibbs FA et al (1941) Electroencephalographic classification of the epilepsies. Arch Neurol Psychiatry 45:903. doi:10.1001/archneurpsyc.1941.02280180015001 CrossRef

56.

Glauser TA, Cnaan A, Shinnar S et al (2010) Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 362:790–799. doi:10.1056/NEJMoa0902014 PubMedPubMedCentralCrossRef

57.

Berg AT, Levy SR, Testa FM, Blumenfeld H (2014) Long-term seizure remission in childhood absence epilepsy: might initial treatment matter? Epilepsia 55:551–557. doi:10.1111/epi.12551 PubMedPubMedCentralCrossRef

58.

Bomben VC, Aiba I, Qian J et al (2016) Isolated P/Q calcium channel deletion in layer VI corticothalamic neurons generates absence epilepsy. J Neurosci 36:405–418. doi:10.1523/JNEUROSCI.2555-15.2016 PubMedPubMedCentralCrossRef

59.

Szaflarski JP, Kay B, Gotman J et al (2013) The relationship between the localization of the generalized spike and wave discharge generators and the response to valproate. Epilepsia 54:471–480. doi:10.1111/epi.12062 PubMedPubMedCentralCrossRef

60.

International League Against Epilepsy Consortium on Complex Epilepsies (2014) Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurol 13:893–903. doi:10.1016/S1474-4422(14)70171-1 CrossRef

61.

Lal D, Ruppert A-K, Trucks H et al (2015) Burden analysis of rare microdeletions suggests a strong impact of neurodevelopmental genes in genetic generalised epilepsies. PLoS Genet 11:e1005226. doi:10.1371/journal.pgen.1005226 PubMedPubMedCentralCrossRef

62.

Chung W-C, Hung S-I, Hong H-S et al (2004) A marker for Stevens–Johnson syndrome. Nature 428:386. doi:10.1038/428486a CrossRef

63.

Chen P, Lin J-J, Lu C-S et al (2011) Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 364:1126–1133. doi:10.1056/NEJMoa1009717 PubMedCrossRef

64.

Horn CS, Ater SB, Hurst DL (1986) Carbamazepine-exacerbated epilepsy in children and adolescents. Pediatr Neurol 2:340–345. doi:10.1016/0887-8994(86)90074-3 PubMedCrossRef

65.

Guerrini R, Dravet C, Genton P et al (1998) Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 39:508–512. doi:10.1111/j.1528-1157.1998.tb01413.x PubMedCrossRef

66.

Snoeijen-Schouwenaars FM, Veendrick MJBM, van Mierlo P et al (2015) Carbamazepine and oxcarbazepine in adult patients with Dravet syndrome: friend or foe? Seizure 29:114–118. doi:10.1016/j.seizure.2015.03.010 PubMedCrossRef

67.

Claes L, Del-Favero J, Ceulemans B et al (2001) De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 68:1327–1332. doi:10.1086/320609 PubMedPubMedCentralCrossRef

68.

Oliva M, Berkovic SF, Petrou S (2012) Sodium channels and the neurobiology of epilepsy. Epilepsia 53:1849–1859. doi:10.1111/j.1528-1167.2012.03631.x PubMedCrossRef

69.

Morgan LA, Millichap JJ (2015) Spectrum of SCN8A-related epilepsy. Pediatr Neurol Briefs 29:16. doi:10.15844/pedneurbriefs-29-2-7 PubMedPubMedCentralCrossRef

70.

Blanchard MG, Willemsen MH, Walker JB et al (2015) De novo gain-of-function and loss-of-function mutations of SCN8A in patients with intellectual disabilities and epilepsy. J Med Genet 52:330–337. doi:10.1136/jmedgenet-2014-102813 PubMedPubMedCentralCrossRef

71.

Boerma RS, Braun KP, van de Broek MPH et al (2016) Remarkable phenytoin sensitivity in 4 children with SCN8A-related epilepsy: a molecular neuropharmacological approach. Neurotherapeutics 13:192–197. doi:10.1007/s13311-015-0372-8 PubMedCrossRef

72.

Klepper J (2008) Glucose transporter deficiency syndrome (GLUT1DS) and the ketogenic diet. Epilepsia 49:46–49. doi:10.1111/j.1528-1167.2008.01833.x PubMedCrossRef

73.

Leen WG, Taher M, Verbeek MM et al (2014) GLUT1 deficiency syndrome into adulthood: a follow-up study. J Neurol 261:589–599. doi:10.1007/s00415-014-7240-z PubMedCrossRef

74.

Wickenden AD, Yu W, Zou A et al (2000) Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 58:591–600. doi:10.1124/mol.58.3.591 PubMed

75.

Millichap J, Park K, Tsuchida T et al (2016) KCNQ2 encephalopathy. Neurol Genet. doi:10.1212/NXG.0000000000000096 PubMedPubMedCentral

76.

Garin Shkolnik T, Feuerman H, Didkovsky E et al (2014) Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. JAMA Dermatol 150:984–989. doi:10.1001/jamadermatol.2013.8895 PubMedCrossRef

77.

Li D, Yuan H, Ortiz-Gonzalez XR et al (2016) GRIN2D recurrent de novo dominant mutation causes a severe epileptic encephalopathy treatable with NMDA receptor channel blockers. Am J Hum Genet. doi:10.1016/j.ajhg.2016.07.013

78.

Milligan CJ, Li M, Gazina EV et al (2014) KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann Neurol 75:581–590. doi:10.1002/ana.24128 PubMedPubMedCentralCrossRef

79.

Mikati MA, Jiang Y, Carboni M et al (2015) Quinidine in the treatment of KCNT1-positive epilepsies. Ann Neurol 78:995–999. doi:10.1002/ana.24520 PubMedPubMedCentralCrossRef

80.

Guerrini R, Dobyns WB (2014) Malformations of cortical development: clinical features and genetic causes. Lancet Neurol 13:710–726. doi:10.1016/S1474-4422(14)70040-7 PubMedCrossRef

81.

Krueger DA, Care MM, Holland K et al (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801–1811. doi:10.1056/NEJMoa1001671 PubMedCrossRef

82.

Russo E, Citraro R, Donato G et al (2013) mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. Neuropharmacology 69:25–36. doi:10.1016/j.neuropharm.2012.09.019 PubMedCrossRef

83.

French JA, Lawson JA, Yapici Z et al (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 6736:1–11. doi:10.1016/S0140-6736(16)31419-2

84.

Sosanya NM, Brager DH, Wolfe S et al (2015) Rapamycin reveals an mTOR-independent repression of Kv1.1 expression during epileptogenesis. Neurobiol Dis 73:96–105. doi:10.1016/j.nbd.2014.09.011 PubMedCrossRef

85.

Dalmau J, Gleichman AJ, Hughes EG et al (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7:1091–1098. doi:10.1016/S1474-4422(08)70224-2 PubMedPubMedCentralCrossRef

86.

Ramaswamy V, Walsh JG, Sinclair DB et al (2013) Inflammasome induction in Rasmussen’s encephalitis: cortical and associated white matter pathogenesis. J Neuroinflammation 10:918. doi:10.1186/1742-2094-10-152 CrossRef

87.

Aronica E, Ravizza T, Zurolo E, Vezzani A (2012) Astrocyte immune responses in epilepsy. Glia 60:1258–1268. doi:10.1002/glia.22312 PubMedCrossRef

88.

Balosso S, Ravizza T, Aronica E, Vezzani A (2013) The dual role of TNF-α and its receptors in seizures. Exp Neurol 247:267–271. doi:10.1016/j.expneurol.2013.05.010 PubMedCrossRef

89.

Prabowo A, Iyer A, Anink J et al (2013) Differential expression of major histocompatibility complex class I in developmental glioneuronal lesions. J Neuroinflammation 10:12. doi:10.1186/1742-2094-10-12 PubMedPubMedCentralCrossRef

90.

Hoda U, Agarwal NB, Vohora D et al (2016) Resveratrol suppressed seizures by attenuating IL-1β, IL1-Ra, IL-6, and TNF-α in the hippocampus and cortex of kindled mice. Nutr Neurosci. doi:10.1080/1028415X.2016.1189057 PubMed

91.

Vezzani A, French J, Bartfai T, Baram TZ (2011) The role of inflammation in epilepsy. Nat Rev Neurol 7:31–40. doi:10.1038/nrneurol.2010.178 PubMedCrossRef

92.

Maroso M, Balosso S, Ravizza T et al (2011) Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics 8:304–315. doi:10.1007/s13311-011-0039-z PubMedPubMedCentralCrossRef

93.

Janigro D (2012) Are you in or out? Leukocyte, ion, and neurotransmitter permeability across the epileptic blood-brain barrier. Epilepsia 53:26–34. doi:10.1111/j.1528-1167.2012.03472.x PubMedPubMedCentralCrossRef

94.

Janigro D, Iffland PH, Marchi N, Granata T (2013) A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches. Epilepsia 54:30–32. doi:10.1111/epi.12271 PubMedPubMedCentralCrossRef

95.

Zurolo E, Iyer A, Maroso M et al (2013) Activation of TLR, RAGE and HMGB1 signaling in malformations of cortical development. Brain 134:1015–1032. doi:10.1093/brain/awr032 CrossRef

96.

Iyer A, Zurolo E, Spliet WGM et al (2010) Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias. Epilepsia 51:1763–1773. doi:10.1111/j.1528-1167.2010.02547.x PubMedCrossRef

97.

de Vries EE, van den Munckhof B, Braun KPJ et al (2016) Inflammatory mediators in human epilepsy: a systematic review and meta-analysis. Neurosci Biobehav Rev 63:177–190. doi:10.1016/j.neubiorev.2016.02.007 PubMedCrossRef

98.

Diamond ML, Ritter AC, Failla MD et al (2014) IL-1-β associations with posttraumatic epilepsy development: a genetics and biomarker cohort study. Epilepsia 55:1109–1119. doi:10.1111/epi.12628 PubMedPubMedCentralCrossRef

99.

Kwon YS, Pineda E, Auvin S et al (2013) Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain. J Neuroinflammation 10:30. doi:10.1186/1742-2094-10-30 PubMedPubMedCentralCrossRef

100.

Jyonouchi H, Geng L (2016) Intractable epilepsy (IE) and responses to anakinra, a human recombinant IL-1 receptor agonist (IL-1ra): case reports. J Clin Cell Immunol 7:1–5. doi:10.4172/2155-9899.1000456

101.

Dibbens LM, de Vries B, Donatello S et al (2013) Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet 45:546–551. doi:10.1038/ng.2599 PubMedCrossRef

102.

Scheffer IE, Heron SE, Regan BM et al (2014) Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations. Ann Neurol 75:782–787. doi:10.1002/ana.24126 PubMedCrossRef

103.

Baulac S, Ishida S, Marsan E et al (2015) Familial focal epilepsy with focal cortical dysplasia due to DEPDC 5 mutations. Ann Neurol 77:675–683. doi:10.1002/ana.24368 PubMedCrossRef

104.

Weckhuysen S, Marsan E, Lambrecq V et al (2016) Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia. Epilepsia 57:994–1003. doi:10.1111/epi.13391 PubMedCrossRef

105.

Christensen J, Pedersen MG, Pedersen CB et al (2009) Long-term risk of epilepsy after traumatic brain injury in children and young adults: a population-based cohort study. Lancet 373:1105–1110. doi:10.1016/S0140-6736(09)60214-2 PubMedCrossRef

106.

Annegers JF, Hauser A, Rocca WA (1998) A population-based study of seizures brain injuries. N Engl J Med 338:20–24. doi:10.1056/NEJM199801013380104 PubMedCrossRef

107.

Marson AG, Al-Kharusi AM, Alwaidh M et al (2007) The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet (London, England) 369:1000–1015. doi:10.1016/S0140-6736(07)60460-7 CrossRef

108.

Glauser T, Ben-Menachem E, Bourgeois B et al (2013) Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 54:551–563. doi:10.1111/epi.12074 PubMedCrossRef

109.

Baulac M, Brodie MJ, Patten A et al (2012) Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 11:579–588. doi:10.1016/S1474-4422(12)70105-9 PubMedCrossRef

110.

Leitinger M, Trinka E, Gardella E et al (2016) Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a retrospective study. Lancet Neurol 15:1054–1062. doi:10.1016/S1474-4422(16)30137-5 PubMedCrossRef

111.

Pohlmann-Eden B, Marson AG, Noack-Rink M et al (2016) Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. BMC Neurol 16:149. doi:10.1186/s12883-016-0663-7 PubMedPubMedCentralCrossRef

112.

Afra P, Adamolekun B (2012) Lacosamide treatment of juvenile myoclonic epilepsy. Seizure 21:202–204. doi:10.1016/j.seizure.2011.12.010 PubMedCrossRef

113.

Yates S, Wechsler R, Beller C (2014) Lacosamide for uncontrolled primary generalized tonic-clonic seizures: an open-label extension study (P3.276). Neurology 82(P3):276

114.

French JA, Krauss GL, Wechsler RT et al (2015) Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial. Neurology 85:950–957. doi:10.1212/WNL.0000000000001930 PubMedPubMedCentralCrossRef

115.

Gowers WR (1881) Epilepsy and other chronic convulsive disorders. Churchill, London

116.

Feigenbaum JJ, Bergmann F, Richmond SA et al (1989) Nonpsychotropic cannabinoid acts as a functional N-methyl-d-aspartate receptor blocker. Proc Natl Acad Sci USA 86:9584–9587PubMedPubMedCentralCrossRef

117.

Devinsky O, Cilio MR, Cross H et al (2014) Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55:791–802. doi:10.1111/epi.12631 PubMedPubMedCentralCrossRef

118.

Porter BE, Jacobson C (2013) Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 29:574–577. doi:10.1016/j.yebeh.2013.08.037 PubMedPubMedCentralCrossRef

119.

Devinsky O, Marsh E, Friedman D et al (2016) Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 15:270–278. doi:10.1016/S1474-4422(15)00379-8 PubMedCrossRef

120.

Young S (2013) Marijuana stops child’s severe seizures-CNN.com. In: CNN. http://edition.cnn.com/2013/08/07/health/charlotte-child-medical-marijuana/. Accessed 18 Dec 2016

121.

Soltesz I, Alger BE, Kano M et al (2015) Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy. Nat Rev Neurosci 16:264–277. doi:10.1038/nrn3937 PubMedCrossRef

122.

Volkow ND, Baler RD, Compton WM, Weiss SRB (2014) Adverse health effects of marijuana use. N Engl J Med 370:2219–2227. doi:10.1056/NEJMra1402309 PubMedPubMedCentralCrossRef

123.

Ottman R, Lipton RB, Ettinger AB et al (2011) Comorbidities of epilepsy: results from the epilepsy comorbidities and health (EPIC) survey. Epilepsia 52:308–315. doi:10.1111/j.1528-1167.2010.02927.x PubMed

124.

Caplan R, Siddarth P, Stahl L et al (2008) Childhood absence epilepsy: behavioral, cognitive, and linguistic comorbidities. Epilepsia 49:1838–1846. doi:10.1111/j.1528-1167.2008.01680.x PubMedCrossRef

125.

Camfield CS, Camfield PR (2007) Long-term social outcomes for children with epilepsy. Epilepsia 48:3–5. doi:10.1111/j.1528-1167.2007.01390.x PubMedCrossRef

126.

Ferro MA, Camfield CS, Levin SD et al (2013) Trajectories of health-related quality of life in children with epilepsy: a cohort study. Epilepsia 54:1889–1897. doi:10.1111/epi.12388 PubMedCrossRef

127.

Jones JE, Watson R, Sheth R et al (2007) Psychiatric comorbidity in children with new onset epilepsy. Dev Med Child Neurol 49:493–497. doi:10.1111/j.1469-8749.2007.00493.x PubMedCrossRef

128.

Hesdorffer DC, Ishihara L, Mynepalli L et al (2012) Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol 72:184–191. doi:10.1002/ana.23601 PubMedCrossRef

129.

Mazarati A, Sankar R (2016) Common mechanisms underlying epileptogenesis and the comorbidities of epilepsy. Cold Spring Harb Perspect Med 6:1–18. doi:10.1101/cshperspect.a022798 CrossRef

130.

Lothe A, Didelot A, Hammers A et al (2008) Comorbidity between temporal lobe epilepsy and depression: a [18 F] MPPF PET study. Brain 131:2765–2782. doi:10.1093/brain/awn194 PubMedCrossRef

131.

Martinez A, Finegersh A, Cannon DM et al (2013) The 5-HT1A receptor and 5-HT transporter in temporal lobe epilepsy. Neurology 80:1465–1471. doi:10.1212/WNL.0b013e31828cf809 PubMedPubMedCentralCrossRef

132.

Larkin GL, Beautrais AL (2011) A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 14:1127–1131. doi:10.1017/S1461145711000629 PubMedCrossRef

133.

Schmitz B (2002) Antidepressant drugs: indications and guidelines for use in epilepsy. Epilepsia 43:14–18. doi:10.1046/j.1528-1157.2002.043s2014.x PubMedCrossRef

134.

Harden CL, Goldstein MA (2002) Mood disorders in patients with epilepsy. CNS Drugs 16:291–302. doi:10.2165/00023210-200216050-00002 PubMedCrossRef

135.

Cardamone L, Salzberg M, O’Brien T, Jones N (2013) Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder? Br J Pharmacol 168:1531–1554. doi:10.1111/bph.12052 PubMedPubMedCentralCrossRef

136.

Kanner AM (2016) Most antidepressant drugs are safe for patients with epilepsy at therapeutic doses: a review of the evidence. Epilepsy Behav 61:282–286. doi:10.1016/j.yebeh.2016.03.022 PubMedCrossRef

137.

Faingold CL, Randall M, Zeng C et al (2016) Serotonergic agents act on 5-HT3 receptors in the brain to block seizure-induced respiratory arrest in the DBA/1 mouse model of SUDEP. Epilepsy Behav 64:166–170. doi:10.1016/j.yebeh.2016.09.034 PubMedCrossRef

138.

Boylan LS, Flint LA, Labovitz DL et al (2004) Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurology 62:258–261. doi:10.1212/01.WNL.0000103282.62353.85 PubMedCrossRef

139.

Campbell E, Kennedy F, Russell A et al (2014) Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry 85:1029–1034. doi:10.1136/jnnp-2013-306318 PubMedCrossRef

140.

Patel SI, Pennell PB (2016) Management of epilepsy during pregnancy: an update. Ther Adv Neurol Disord 9:118–129. doi:10.1177/1756285615623934 PubMedCrossRef

141.

Hernandez S, Shen A, Holmes LB (2012) Comparative safety of antiepileptic drugs during pregnancy For the North American. Neurology 78:1692–1699. doi:10.1212/WNL.0b013e3182574f39 CrossRef

142.

Mawhinney E, Craig J, Morrow J et al (2013) Levetiracetam in pregnancy. Neurology 80:400–405. doi:10.1212/WNL.0b013e31827f0874 PubMedCrossRef

143.

Meador KJ, Baker GA, Browning N et al (2013) Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 12:244–252. doi:10.1016/S1474-4422(12)70323-X PubMedPubMedCentralCrossRef

144.

Christensen J (2013) Prenatal valproate exposure and risk of autism spectrum disorders. JAMA 309:1696–1703. doi:10.1001/jama.2013.2270 PubMedPubMedCentralCrossRef

145.

Bromley RL, Mawer GE, Briggs M et al (2013) The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry 84:637–643. doi:10.1136/jnnp-2012-304270 PubMedPubMedCentralCrossRef

146.

Veiby G, Engelsen BA, Gilhus NE et al (2013) Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding. JAMA Neurol 70:1367. doi:10.1001/jamaneurol.2013.4290 PubMedCrossRef

147.

Hernández-Díaz S, Mittendorf R, Smith CR et al (2014) Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstet Gynecol 123:21–28. doi:10.1097/AOG.0000000000000018 PubMedCrossRef

148.

Campbell E, Devenney E, Morrow J et al (2013) Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia 54:165–171. doi:10.1111/epi.12001 PubMedCrossRef

149.

Vajda FJE, O’Brien TJ, Lander CM et al (2013) Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia 54:181–186. doi:10.1111/j.1528-1167.2012.03625.x PubMedCrossRef

150.

Edey S, Moran N, Nashef L (2014) SUDEP and epilepsy-related mortality in pregnancy. Epilepsia 55:72–74. doi:10.1111/epi.12621 CrossRef

151.

Jobst BC, Cascino GD, R K et al (2015) Resective epilepsy surgery for drug-resistant focal epilepsy. JAMA 313:285. doi:10.1001/jama.2014.17426 PubMedCrossRef

152.

Englot DJ, Ouyang D, Garcia PA et al (2012) Epilepsy surgery trends in the United States, 1990–2008. Neurology 78:1200–1206. doi:10.1212/WNL.0b013e318250d7ea PubMedPubMedCentralCrossRef

153.

Helmstaedter C, May TW, von Lehe M et al (2014) Temporal lobe surgery in Germany from 1988 to 2008: diverse trends in etiological subgroups. Eur J Neurol 21:827–834. doi:10.1111/ene.12322 PubMedCrossRef

154.

Shorvon S, Tomson T (2011) Sudden unexpected death in epilepsy. Lancet 378:2028–2038. doi:10.1016/S0140-6736(11)60176-1 PubMedCrossRef

155.

Tebo CC, Evins AI, Christos PJ et al (2014) Evolution of cranial epilepsy surgery complication rates: a 32-year systematic review and meta-analysis. J Neurosurg 120:1415–1427. doi:10.3171/2014.1.JNS131694 PubMedCrossRef

156.

Bjellvi J, Flink R, Rydenhag B, Malmgren K (2015) Complications of epilepsy surgery in Sweden 1996–2010: a prospective, population-based study. J Neurosurg 122:519–525. doi:10.3171/2014.9.JNS132679 PubMedCrossRef

157.

Menon R, Rathore C, Sarma SP, Radhakrishnan K (2012) Feasibility of antiepileptic drug withdrawal following extratemporal resective epilepsy surgery. Neurology 79:770–776. doi:10.1212/WNL.0b013e3182644f7d PubMedCrossRef

158.

Yardi R, Irwin A, Kayyali H et al (2014) Reducing versus stopping antiepileptic medications after temporal lobe surgery. Ann Clin Transl Neurol 1:115–123. doi:10.1002/acn3.35 PubMedPubMedCentralCrossRef

159.

Taft C, Sager Magnusson E, Ekstedt G, Malmgren K (2014) Health-related quality of life, mood, and patient satisfaction after epilepsy surgery in Sweden—a prospective controlled observational study. Epilepsia 55:878–885. doi:10.1111/epi.12616 PubMedPubMedCentralCrossRef

160.

Picot M-C, Jaussent A, Neveu D et al (2016) Cost-effectiveness analysis of epilepsy surgery in a controlled cohort of adult patients with intractable partial epilepsy: a 5-year follow-up study. Epilepsia 57:1669–1679. doi:10.1111/epi.13492 PubMedCrossRef

161.

Edelvik A, Rydenhag B, Olsson I et al (2013) Long-term outcomes of epilepsy surgery in Sweden: a national prospective and longitudinal study. Neurology 81:1244–1251. doi:10.1212/WNL.0b013e3182a6ca7b PubMedPubMedCentralCrossRef

162.

Rydenhag B, Flink R, Malmgren K (2013) Surgical outcomes in patients with epileptogenic tumours and cavernomas in Sweden: good seizure control but late referrals. J Neurol Neurosurg Psychiatry 84:49–53. doi:10.1136/jnnp-2012-302449 PubMedCrossRef

163.

Ding D, Quigg M, Starke R et al (2015) Predictors of seizure improvement following stereotactic radiosurgery for cerebral arteriovenous malformations in a prospective cohort of 229 patients with AVM-associated epilepsy (P1.001). Neurology 84(P1):001

164.

Przybylowski CJ, Ding D, Starke RM et al (2015) Seizure and anticonvulsant outcomes following stereotactic radiosurgery for intracranial arteriovenous malformations. J Neurosurg 122:1299–1305. doi:10.3171/2014.11.JNS141388 PubMedCrossRef

165.

Ditty BJ, Omar NB, Foreman PM et al (2016) Seizure outcomes after stereotactic radiosurgery for the treatment of cerebral arteriovenous malformations. J Neurosurg. doi:10.3171/2015.12.JNS152461 PubMed

166.

Feng E-S, Sui C-B, Wang T-X, Sun G-L (2016) Stereotactic radiosurgery for the treatment of mesial temporal lobe epilepsy. Acta Neurol Scand 134:442–451. doi:10.1111/ane.12562 PubMedCrossRef

167.

Waseem H, Osborn KE, Schoenberg MR et al (2015) Laser ablation therapy: an alternative treatment for medically resistant mesial temporal lobe epilepsy after age 50. Epilepsy Behav 51:152–157. doi:10.1016/j.yebeh.2015.07.022 PubMedCrossRef

168.

Ribot R, Jagid J, Serrano E et al (2015) MRI-guided stereotactic laser ablation of mesial temporal structures for the treatment of refractory temporal lobe epilepsy (S31.008). Neurology 84(S31):008

169.

Gonzalez-Martinez J, Vadera S, Mullin J et al (2014) Robot-assisted stereotactic laser ablation in medically intractable epilepsy. Neurosurgery 10:167–173. doi:10.1227/NEU.0000000000000286 PubMedCrossRef

170.

Willie JT, Laxpati NG, Drane DL et al (2014) Real-time magnetic resonance-guided stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy. Neurosurgery 74:569–584. doi:10.1227/NEU.0000000000000343 PubMedPubMedCentralCrossRef

171.

Wellmer J, Voges J, Parpaley Y (2016) Lesion guided radiofrequency thermocoagulation (L-RFTC) for hypothalamic hamartomas, nodular heterotopias and cortical dysplasias: review and perspective. Seizure 41:206–210. doi:10.1016/j.seizure.2016.05.013 PubMedCrossRef

172.

de Tisi J, Bell GS, Peacock JL et al (2011) The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study. Lancet 378:1388–1395. doi:10.1016/S0140-6736(11)60890-8 PubMedCrossRef

173.

Gonzalez-Martinez J, Bulacio J, Alexopoulos A et al (2013) Stereoelectroencephalography in the “difficult to localize” refractory focal epilepsy: early experience from a North American epilepsy center. Epilepsia 54:323–330. doi:10.1111/j.1528-1167.2012.03672.x PubMedCrossRef

174.

Coan AC, Kubota B, Bergo FPG et al (2014) 3T MRI quantification of hippocampal volume and signal in mesial temporal lobe epilepsy improves detection of hippocampal sclerosis. AJNR Am J Neuroradiol 35:77–83. doi:10.3174/ajnr.A3640 PubMedCrossRef

175.

Mellerio C, Labeyrie M-A, Chassoux F et al (2014) 3T MRI improves the detection of transmantle sign in type 2 focal cortical dysplasia. Epilepsia 55:117–122. doi:10.1111/epi.12464 PubMedCrossRef

176.

De Ciantis A, Barba C, Tassi L et al (2016) 7 T MRI in focal epilepsy with unrevealing conventional field strength imaging. Epilepsia 57:445–454. doi:10.1111/epi.13313 PubMedCrossRef

177.

Rathore C, Dickson JC, Teotónio R et al (2014) The utility of 18F-fluorodeoxyglucose PET (FDG PET) in epilepsy surgery. Epilepsy Res 108:1306–1314. doi:10.1016/j.eplepsyres.2014.06.012 PubMedCrossRef

178.

Yang P-F, Pei J-S, Zhang H-J et al (2014) Long-term epilepsy surgery outcomes in patients with PET-positive, MRI-negative temporal lobe epilepsy. Epilepsy Behav 41:91–97. doi:10.1016/j.yebeh.2014.09.054 PubMedCrossRef

179.

Bagić A (2016) Look back to leap forward: the emerging new role of magnetoencephalography (MEG) in nonlesional epilepsy. Clin Neurophysiol 127:60–66. doi:10.1016/j.clinph.2015.05.009 PubMedCrossRef

180.

Murakami H, Wang ZI, Marashly A et al (2016) Correlating magnetoencephalography to stereo-electroencephalography in patients undergoing epilepsy surgery. Brain 139:2935–2947. doi:10.1093/brain/aww215 CrossRef

181.

Lascano AM, Perneger T, Vulliemoz S et al (2016) Yield of MRI, high-density electric source imaging (HD-ESI), SPECT and PET in epilepsy surgery candidates. Clin Neurophysiol 127:150–155. doi:10.1016/j.clinph.2015.03.025 PubMedCrossRef

182.

Oxley TJ, Opie NL, John SE et al (2016) Minimally invasive endovascular stent-electrode array for high-fidelity, chronic recordings of cortical neural activity. Nat Biotechnol 34:320–327. doi:10.1038/nbt.3428 PubMedCrossRef

183.

Révész D, Rydenhag B, Ben-Menachem E (2016) Complications and safety of vagus nerve stimulation: 25 years of experience at a single center. J Neurosurg Pediatr 18:97–104. doi:10.3171/2016.1.PEDS15534 PubMedCrossRef

184.

Englot DJ, Rolston JD, Wright CW et al (2016) Rates and predictors of seizure freedom with vagus nerve stimulation for intractable epilepsy. Neurosurgery 79:345–353. doi:10.1227/NEU.0000000000001165 PubMedCrossRef

185.

Ryvlin P, Gilliam FG, Nguyen DK et al (2014) The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PuLsE (open prospective randomized long-term effectiveness) trial. Epilepsia 55:893–900. doi:10.1111/epi.12611 PubMedPubMedCentralCrossRef

186.

Martin JLR, Martín-Sánchez E (2012) Systematic review and meta-analysis of vagus nerve stimulation in the treatment of depression: variable results based on study designs. Eur Psychiatry 27:147–155. doi:10.1016/j.eurpsy.2011.07.006 PubMedCrossRef

187.

Heck CN, King-Stephens D, Massey AD et al (2014) Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: final results of the RNS system pivotal trial. Epilepsia 55:432–441. doi:10.1111/epi.12534 PubMedPubMedCentralCrossRef

188.

Salanova V, Witt T, Worth R et al (2015) Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. Neurology 84:1017–1025. doi:10.1212/WNL.0000000000001334 PubMedPubMedCentralCrossRef

189.

Kowski AB, Voges J, Heinze H-J et al (2015) Nucleus accumbens stimulation in partial epilepsy-A randomized controlled case series. Epilepsia 56:e78–e82. doi:10.1111/epi.12999 PubMedCrossRef

190.

Kros L, Eelkman Rooda OHJ, De Zeeuw CI, Hoebeek FE (2015) Controlling cerebellar output to treat refractory epilepsy. Trends Neurosci 38:787–799. doi:10.1016/j.tins.2015.10.002 PubMedCrossRef

191.

Krook-Magnuson E, Armstrong C, Oijala M et al (2013) On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy. Nat Commun 4:1376. doi:10.1038/ncomms2376 PubMedPubMedCentralCrossRef

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Recent advances in epilepsy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2017

Driving with a neurodegenerative disorder: an overview of the current literature

HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment

Mutations in GFPT1-related congenital myasthenic syndromes are associated with synaptic morphological defects and underlie a tubular aggregate myopathy with synaptopathy

Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis

Phenytoin: 80 years young, from epilepsy to breast cancer, a remarkable molecule with multiple modes of action

The relevance of gender in Parkinson’s disease: a review